Search PubMed⌕ Search

Biomedical subjects

N Kurata

Publications and source records attributed to N Kurata.

At least 109 records · Page 6Linked to original sources
PubMed1981

Treatment of angina pectoris patients with niludipine a new calcium antagonistic drug.

The antianginal effectivity of niludipine (Bay a 7168), a new calcium antagonistic drug, was investigated in angina pectoris patients, selected for admission to the trials by pre-determined strict criteria. Oral administration of from 60--120 mg niludipine daily for 4--8 weeks, resulted in the following: 1. Number of anginal attacks significantly reduced. 2. Nitrate consumption markedly lowered. 3. Investigating physicians assessed globally the clinical results of niludipine treatment on the basis of the reduction of the number of anginal attacks, nitrate consumption, improved physical ability and reports by the patients as to their subjective evaluation of the test drug. Niludipine was judged clinically effective in 21 out of 27 patients (77.8%). 4. Full records of ECGs, a necessary item for assessment, were obtained from 24 out of 27 patients. Ischemic ECGs were improved or normalized in 6 out of 24 patients (25%). 5. In the investigators' final overall assessment, including the evaluation of ECG changes, niludipine was rated effective for 20 out of 27 patients (74.1%). 6. Tolerance to the test drug was excellent. Only one patient complained of transient, mild nausea. After reduction of the daily dose, the patient completed the trial without any further appearance or complaints of side effects. Results suggest that niludipine is a useful antianginal drug in the management of coronary artery disease patients. Further clinical investigations with a larger number of patients should be conducted.

Aged↗
PubMed1980

Effects of dietary trans acids on the biosynthesis of arachidonic acid in rat liver microsomes.

Effects of dietary trans acids on the interconversion of linoleic acid was studied using the liver microsomal fraction of rats fed a semipurified diet containing fat supplements of safflower oil (SAFF), hydrogenated coconut oil (HCO) at 5 and 20 at and 20% levels or a 5% level of a supplement containing 50.3% linolelaidic and 24.3% elaidic acids devoid of cis,cis-linoleic acid (TRANS). Growth rate was suppressed to greater extent with the animals fed the 20% than the 5% level of the HCO-supplemented diets and still further by the TRANS diet compared to the groups fed the SAFF diets. Food intake was greater in the groups fed the HCO than the SAFF-supplemented diets, demonstrating the marked effect of an essential fatty acid (EFA) deficiency on feed efficiency. In contrast to an EFA deficiency produced by the HCO supplement, which stimulated the in vitro liver microsomal biosynthesis of arachidonic acid, diets containing the TRANS supplement exacerabated the EFA deficiency and depressed 6-desaturase activity of the liver microsomal fraction. The liver microsomal fraction of the animals receiving this supplement also was more sensitive to fatty acid inhibition of the desaturation of linoleic acid than those obtained from animals fed either the SAFF or HCO diets. It is suggested that dietary trans acids alter the physical properties of the 6-desaturase enzyme system, suppressing its activity, which increases the saturation of the tissue lipids and, in turn, the requirement for EFA or polyunsaturated fatty acids.

Animals↗
PubMed1980

Characteristics of antibody to denatured DNA in sera of patients with systemic lupus erythematosus and other rheumatic diseases.

Antibody to native (n-)DNA and denatured (d-)DNA were detected simultaneously and quantitatively in patients who had systemic lupus erythematosus (SLE) and other rheumatic diseases by the Millipore Filter method. In a group of patients who had SLE, 94% had antibody to both n-DNA and d-DNA; 6% had antibody to d-DNA only; serum that had antibody to n-DNA was not found. On the other hand, some of the patients who had progressive systemic sclerosis, dermatomyositis, polymyositis, and Sjøgren's syndrome had antibody to d-DNA only. In order to estimate the participation of anti-d-DNA antibody to lupus nephritis, patients who had SLE were classified into two groups according to immunofluorescent glomerular stainings. In a group of patients whose sera had lumpy or granular stainings, the sera reacted predominantly with n-DNA. In contrast, in the other group of patients whose sera had mesangial or linear glomerular stainings, the sera had antibodies reactive with d-DNA predominantly. These difference of reactivity between the two groups were statistically significant (P less than 0.02). The results suggest that the antibody to d-DNA is less relevant to the severity of lupus nephritis. in the evaluation of disease activity and prognosis of patients who have SLE, it will be of value to estimate the nature of anti-DNA antibodies.

Antibodies, Antinuclear↗